The preventing recurrent vascular events and neurological worsening through intensive organized case-management (PREVENTION) trial protocol [clinicaltrials.gov identifier: NCT00931788]

Implementation Science

Volumn 5, Issue 1, 2010, Pages

  McAlister, Finlay A ^a,b,c   Majumdar, Sumit R ^a   Padwal, Rajdeep S ^a   Fradette, Miriam ^c   Thompson, Ann ^a   Tsuyuki, Ross ^c   Grover, Steven A ^d   Dean, Naeem ^a,e   Shuaib, Ashfaq ^a  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950635237     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/1748-5908-5-27     Document Type: Article

References (63)

1. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913. 10.1016/S0140-6736(02)11911-8, 12493255, Prospective Studies Collaboration.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952. 10.1016/S0140-6736(04)17018-9, 15364185.
3. Blood Pressure Lowering Treatment Trialists Collaboration Effects of different blood pressure lowering regimens on major cardiovascular events: second cycle of prospectively designed overviews. Lancet 2003, 362:1527-1535. 10.1016/S0140-6736(03)14739-3, 14615107, Blood Pressure Lowering Treatment Trialists Collaboration.
4. Cholesterol Treatment Trialists Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. 10.1016/S0140-6736(05)67394-1, 16214597, Cholesterol Treatment Trialists Collaborators.
5. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention: Scientific Review. JAMA 2002, 288:1388-1395. 10.1001/jama.288.11.1388, 12234233.
6. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke. A quantitative modeling study. Stroke 2007, 38:1881-1885. 10.1161/STROKEAHA.106.475525, 17431209.
7. Mouradian MS, Hussain MS, Lari H, Salam A, Senthilselvan A, Dean N, Shuaib A. The impact of a stroke prevention clinic in diagnosing modifiable risk factors for stroke. Can J Neurol Sci 2005, 32:496-500.
8. Mouradian MS, Majumdar SR, Senthilselvan A, Khan K, Shuaib A. How well are hypertension, hyperlipidemia, diabetes, and smoking managed after a stroke or transient ischemic attack?. Stroke 2002, 33:1656-1659. 10.1161/01.STR.0000017877.62543.14, 12053007.
9. Lindsay P, Bayley M, McDonald A, Lindsay P, Bayley M, McDonald A, Graham ID, Warner G, Phillips S. Toward a more effective approach to stroke: Canadian Best Practice Recommendations for Stroke Care. CMAJ 2008, 178:1418-1425. 2374857, 18490636.
10. Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack. A population-based study. Neurology 2004, 62:2015-2020.
11. Joseph LN, Babikian VL, Allen NC, Winter MR. Risk factor modification in stroke prevention. The experience of a stroke clinic. Stroke 1999, 30:16-20.
12. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004, 171:1189-1192. 524949, 15534311.
13. McAlister FA, Oreopoulos A, Norris CM, Graham MM, Tsuyuki RT, Knudtson M, Ghali WA, . for the APPROACH Investigators Exploring the treatment-risk paradox in coronary disease. Arch Intern Med 2007, 167:1019-1025. 10.1001/archinte.167.10.1019, 17533204, for the APPROACH Investigators.
14. Lear SA, Ignaszewksi A, Linden W, Brozic A, Kiess M, Spinelli JJ, Pritchard PH, Frohlich JJ. The extensive lifestyle management intervention (ELMI) following cardiac rehabilitation trial. Eur Heart J 2003, 24:1920-1927. 10.1016/j.ehj.2003.08.015, 14585250.
15. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JNE, Lovelock CE, Binney LE, Bull LM, Cuthbertson FC, Welch SJV, Bosch S, Carasco-Alexander F, Silver LE, Gutnikov SA, Mehta Z. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007, 370:1432-1442. 10.1016/S0140-6736(07)61448-2, 17928046.
16. Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997, 10:1097-1102. 10.1016/S0895-7061(97)00224-0, 9370379.
17. Ezzati M, Lopez AD, Rodgers A, Hoorn S, Murrary CJL, . the Comparative Risks Assessment Collaborating Group Selected major risk factors and global and regional burden of disease. Lancet 2002, 360:1347-1360. 10.1016/S0140-6736(02)11403-6, 12423980, the Comparative Risks Assessment Collaborating Group.
18. Kaplan RC, Tirschwell DL, Longstreth WT, Manolio TA, Heckbert SR, Lefkowitz D, El-Saed A, Psaty BM. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. Neurology 2005, 65:835-842. 10.1212/01.wnl.0000176058.09848.bb, 16186519.
19. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041. 10.1016/S0140-6736(01)06178-5, 11589932, PROGRESS Collaborative Group.
20. Gueyffier F, Boissel J-P, Boutitie F, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Kerlikowske K, Perry M, Prineas R, Schron E. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997, 28:2557-2562.
21. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, MacMahon S, Neal B. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006, 24:1201-1208. 10.1097/01.hjh.0000226212.34055.86, 16685221.
22. Blood Pressure Lowering Treatment Trialists' Collaboration Blood pressure-dependent and independent effects of agents that inhibit the rennin-angiotensin system. J Hypertens 2007, 25:951-958. 10.1097/HJH.0b013e3280bad9b4, 17414657, Blood Pressure Lowering Treatment Trialists' Collaboration.
23. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BPL, Chen S, Cunha L, Dahlof B, de Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon B. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-1237. 10.1056/NEJMoa0804593, 2714258, 18753639.
24. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174-1183. 10.1016/S0140-6736(08)61242-8, 18757085, The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators.
25. SPARCL Investigators High dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006, 355:549-559. 10.1056/NEJMoa061894, 16899775, SPARCL Investigators.
26. Amarenco P, Goldstein LB, Szarek M. Effects of intensive LDL-C reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 2007, 38:3198-3204. 10.1161/STROKEAHA.107.493106, 17962589.
27. Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 2008, 178:576-584. 2244680, 18299547.
28. Majumdar SR, McAlister FA, Furberg CD. From publication to practice in chronic cardiovascular disease- the long and winding road. J Am Coll Cardiol 2004, 43:1738-1742. 10.1016/j.jacc.2003.12.043, 15145092.
29. McAlister FA, Man-Son-Hing M, Straus SE, Ghali WA, Anderson D, Majumdar SR, Gibson P, Cox J, Fradette M, . for the DAAFI Investigators The impact of patient decision aids on care in patients with atrial fibrillation: a cluster randomized trial. CMAJ 2005, 173:496-501. 1188186, 16129870, for the DAAFI Investigators.
30. Majumdar SR, Guirguis LM, Toth EL, Lewanczuk RZ, Lee TK, Johnson JA. Controlled trial of a multifaceted intervention for improving quality of care for rural patients with type 2 diabetes. Diabetes Care 2003, 26:3061-3066. 10.2337/diacare.26.11.3061, 14578240.
31. Majumdar SR, Johnson JA, Lier DA, Russell AS, Hanley DA, Blitz S, Steiner IP, Maksymowych WP, Morrish DW, Holroyd BR, Rowe BH. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporosis Int 2007, 18:261-270.
32. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, Cave A, Chang WC, Dzavik V, Farris KB, Galvin D, Semchuk W, Taylor JG, . for the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) Investigators A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002, 162:1149-1155. 10.1001/archinte.162.10.1149, 12020186, for the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) Investigators.
33. Majumdar SR, Tsuyuki RT, McAlister FA. Impact of opinion leader endorsed evidence summaries on quality of prescribing for patients with cardiovascular disease: randomized controlled trial. Am Heart J 2007, 153:22-29. 10.1016/j.ahj.2006.07.030, 17174632.
34. McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, Tsuyuki RT. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes: SCRIP-HTN. Arch Intern Med 2008, 168:2355-2361. 10.1001/archinte.168.21.2355, 19029501.
35. McAlister FA, Fradette M, Majumdar SR, Graham M, Williams R, McMeekin J, Ghali WA, Tsuyuki RT, Knudtson ML, Grimshaw J. The enhancing secondary prevention in coronary artery disease trial. CMAJ 2009, 181:897-904. 2789127, 19933787.
36. Clark AM, Hartling L, Vandermeer B, McAlister FA. Randomized trials of secondary prevention programs in coronary heart disease: a systematic review. Ann Intern Med 2005, 143:659-672.
37. Koelewijn-van Loon MS, Weijden T, van Steenkiste B, Ronda G, Winkens B, Severens JL, Wensing M, Elwyn G, Grolet R. Involving patients in cardiovascular risk management with nurse-led clinics: a cluster randomized controlled trial. CMAJ 2009, 181:E267-E274. 2789146, 19948811.
38. Shojania KG, Ranji SR, McDonald KM, Grimshaw JM, Sundaram V, Rushakoff RJ, Owenset DK. Effects of quality improvement strategies for type 2 diabetes on glycemic control. A meta-regression analysis. JAMA 2006, 296:427-440. 10.1001/jama.296.4.427, 16868301.
39. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharma Assoc 2008, 48:23-31.
40. The Community Pharmacy Medicines Management Project Evaluation Team The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Practice 2007, 24:189-200. The Community Pharmacy Medicines Management Project Evaluation Team.
41. Ellis SL, Carter BL, Malone DC, Billups SJ, Okano GJ, Valuck RJ, Barnette DJ, Sintek CD, Covey D, Mason B, Jue S, Carmichael J, Guthrie K. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Pharmacotherapy 2000, 20:1508-1516. 10.1592/phco.20.19.1508.34852, 11130223.
42. Bozovich M, Rubino CM, Edmunds J. Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. Pharmacotherapy 2000, 20:1375-1383. 10.1592/phco.20.17.1375.34895, 11079286.
43. Till LT, Voris JC, Bourne Horst J. Assessment of clinical pharmacist management of lipid-lowering therapy in a primary care setting. J Managed Care Pharm 2003, 9:269-273.
44. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. A randomized controlled trial (FAME). JAMA 2006, 296:2563-2571. 10.1001/jama.296.21.joc60162, 17101639.
45. Zillich AJ, Sutherland JM, Kumbera PA, Carter BL. Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME Study). J Gen Intern Med 2005, 20:1091-1096. 10.1111/j.1525-1497.2005.0226.x, 1490290, 16423096.
46. Machado M, Bajcar J, Guzzo CG, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother 2007, 41:1770-1781. 10.1345/aph.1K311, 17925496.
47. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database of Systematic Reviews 2006, (4):CD005182. DOI: 10.1002/14651858.CD005182.pub3..
48. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database of Systematic Reviews 2000, (2):CD000336. DOI: 10.1002/14651858.CD000336..
49. Walsh J, McDonald KM, Shojania KG, Sundaram V, Nayak S, Davies S, Lewis R, Mechanic J, Sharp C, Henne M, Shah B, Chan JK, Owens DK, Goldstein MK. Closing the quality gap: a critical analysis of quality improvement strategies. technical review 9. Hypertension Care 2005, 3. (Prepared by the Stanford University-UCSF Evidence-based Practice Center, under Contract No. 290-02-0017). AHRQ Publication No. 04-0051-3. Rockville, MD: Agency for Healthcare Research and Quality, Shojania KG, McDonald KM, Wachter RM, Owens DK.
50. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatric Soc 1975, 23:433-441.
51. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
52. Khan NA, Hemmelgarn B, Herman RJ, . for the Canadian Hypertension Education Program The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol 2008, 24:465-475. 2643190, 18548143, for the Canadian Hypertension Education Program.
53. Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L, Boudreau G. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy. The CHECK-UP Study: A randomized controlled trial. Arch Intern Med 2007, 167:2296-2303. 10.1001/archinte.167.21.2296, 18039987.
54. Grover SA, Lowensteyn I, Joseph L, Kaouache M, Marchand S, Coupal L, Boudreau G. Discussing coronary risk with patients to improve blood pressure treatment: Secondary results from the CHECK-UP Study. J Gen Intern Med 2009, 24:33-9. Epub 2008 Oct 21., 10.1007/s11606-008-0825-4, 2607501, 18937013.
55. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischemic attack. Lancet 2007, 369:283-292. 10.1016/S0140-6736(07)60150-0, 17258668.
56. Wilkins K, Campbell NRC, Joffres MR, McAlister FA, Nichol M, Quach S, Johansen HL, Tremblay MS. Blood pressure in Canadian adults. Health Reports 2010,
57. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003, 34:2741-2748. 10.1161/01.STR.0000092488.40085.15, 14576382.
58. Prospective Studies Collaboration Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007, 370:1829-1839. 10.1016/S0140-6736(07)61778-4, 18061058, Prospective Studies Collaboration.
59. EQ-5D. Last revised: 2009., http://euroqol.org
60. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1998, 19:604-607.
61. Johnstone J, Eurich D, Majumdar SR, Yan J, Marrie TJ. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine 2008, 87:329-334. 10.1097/MD.0b013e318190f444, 19011504.
62. Khanal S, Obeidat O, Hudson MP, Al-Mallah M, Bloome M, Lu M, Greenbaum AB, Kugelmass AD, Weaver WD. Active lipid management in coronary artery disease (ALMICAD) Study. Am J Med 2007, 120:734.e11-734.e17.
63. Tobe SW, Pylypchuk G, Wentworth J, Kiss A, Szalai JP, Perkins N, Hartman S, Ironstand L, Hoppeet J. Effect of nurse-directed hypertension treatment among First Nations people with existing hypertension and diabetes mellitus: the Diabetes Risk Evaluation and Microalbuminuria (DREAM 3) randomized controlled trial. CMAJ 2006, 174:1267-1271. 1435956, 16595786.